RecruitingNCT06895291

Whole Body MRI in Oncology

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Enrollment

1,000 participants

Start Date

Oct 26, 2023

Study Type

OBSERVATIONAL

Conditions

Advanced Breast Cancer Advanced Prostate Cancer Multiple Myeloma Lymphoma Monoclonal Gammopathy of Undetermined Significance Smoldering Multiple Myeloma

Summary

Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how whole-body MRI — a single scan that images the entire body — can be used to better monitor and manage various cancers and other conditions. Unlike multiple separate scans, a whole-body MRI can potentially detect disease in many areas at once, saving time and reducing radiation exposure. Researchers want to understand how useful it is in real clinical practice. **You may be eligible if...** - You are 18 years or older - Your doctor has recommended a whole-body MRI as part of your clinical care - You have a life expectancy of more than 3 months - You are able to provide informed consent **You may NOT be eligible if...** - You have a metal implant or device that is not safe for MRI (such as certain pacemakers or joint replacements) - The quality of your MRI images is not sufficient for analysis - You are pregnant - You are unable to lie still in the MRI machine for the required time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTWhole Body-Magnetic Resonance Imaging (WB-MRI)

This is a non-pharmacological, observational, prospective, study. Each patient will undergo quantitative WB-MRI as per clinical routine. WB-MRI may be performed: * at staging * at follow-up Disease progression is defined by clinicians taking into account all imaging modalities and clinicolaboratorial data available for the patients.

Locations(3)

IRCCS - Azienda Ospedaliero-Universitaria di Bologna - Policlinico di S. Orsola

Bologna, BO, Italy

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.

Meldola, FC, Italy

IRCCS Istituto Europeo di Oncologia S.r.l.

Milan, MI, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06895291

Related Trials

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT061038381 location

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT0617988874 locations

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT052379863 locations

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT059471361 location

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

NCT032585671 location